Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease
Open Access
- 12 January 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (5) , e621-e623
Abstract
Progressive familial intrahepatic cholestasis type 1 (PFIC1) is an inherited, progressive cholestatic liver disease. Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1. The diagnosis of PFIC1 presents a unique challenge in the treatment of Ewing sarcoma, as the standard-of-care vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide chemotherapy backbone for Ewing sarcoma therapy treatment relies heavily on intact hepatic metabolism. In addition, we report prolonged lymphopenia and severe infectious complications in this patient, both of which may be attributed to more severe immunosuppression in setting of poor hepatic metabolism of chemotherapeutic agents.Keywords
This publication has 15 references indexed in Scilit:
- Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical ApplicationScientia Pharmaceutica, 2017
- Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Commentary: Oncologic Drugs in Patients with Organ Dysfunction: A SummaryThe Oncologist, 2007
- Hepatotoxicity of ChemotherapySeminars in Oncology, 2006
- Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumorsPediatric Blood & Cancer, 2006
- Chemotherapy dosing in the setting of liver dysfunction.2005
- Phase I and Pharmacologic Studies of Topotecan in Patients With Impaired Hepatic FunctionJNCI: Journal of the National Cancer Institute, 1996
- Disposition of total and unbound etoposide following high-dose therapyCancer Chemotherapy and Pharmacology, 1993
- Chemotherapeutic agents and hepatotoxicity.1992
- Effect of liver failure on the pharmacokinetics of cyclophosphamideEuropean Journal of Clinical Pharmacology, 1984